A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model

Digestive Diseases and Sciences

Volumn 59, Issue 7, 2014, Pages 1490-1501

  Jia, Xiaofang ^a   Suzuki, Yudai ^a   Naito, Hisao ^a   Yetti, Husna ^a   Kitamori, Kazuya ^a,b   Hayashi, Yumi ^a   Kaneko, Rina ^a   Nomura, Mina ^a   Yamori, Yukio ^c   Zaitsu, Kei ^a   Kato, Masashi ^a   Ishii, Akira ^a   Nakajima, Tamie ^a,d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINJO GAKUIN UNIVERSITY   (Japan)

^c MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^d CHUBU UNIVERSITY   (Japan)

Author keywords

Bile acid profiles; Correlation analysis; Fibrotic steatohepatitis; High fat cholesterol diet

Indexed keywords

ALANINE AMINOTRANSFERASE; BILE ACID CONJUGATE; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; GLYCINE; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL INTAKE; CONTROLLED STUDY; DISEASE ASSOCIATION; EVALUATION STUDY; FEMALE; LIPID DIET; LIVER FIBROSIS; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; CHENODEOXYCHOLIC ACID; CHOLIC ACID; CHROMATOGRAPHY, LIQUID; DEOXYCHOLIC ACID; DIET, HIGH-FAT; FATTY LIVER; LIVER; LIVER CIRRHOSIS; MALE; RANDOM ALLOCATION; RATS; TANDEM MASS SPECTROMETRY;

EID: 84903552014     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3028-3     Document Type: Article

References (42)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395. (Pubitemid 39657013)
2. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820-1832.
3. Savard C, Tartaglione EV, Kuver R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology. 2013;57:81-92.
4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology . 2006;43:S99-S112.
5. Martin FP, Dumas ME, Wang Y, et al. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol. 2007;3:112.
6. Fu ZD, Csanaky IL, Klaassen CD. Gender-divergent profile of bile acid homeostasis during aging of mice. PLoSONE. 2012;7:e32551.
7. Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci. 2009;14:2584-2598.
8. Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009;15:804-816.
9. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999;159:2647-2658.
10. Aranha MM, Cortez-Pinto H, Costa A, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20:519-525. (Pubitemid 351667892)
11. Kitamori K, Naito H, Tamada H, et al. Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. Environ Health Prev Med. 2012;17:173-182.
12. Moriya T, Kitamori K, Naito H, et al. Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat. Environ Health Prev Med. 2012;17:444-456.
13. Jia X, Naito H, Yetti H, et al. The modulation of hepatic adenosine triphosphate and inflammation by eicosapentaenoic acid during severe fibrotic progression in the SHRSP5/Dmcr rat model. Life Sci. 2012;90:934-943.
14. Jia X, Naito H, Yetti H, et al. Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats. Dig Dis Sci. 2013;58:2212-2222.
15. Suzuki Y, Kaneko R, Nomura M, et al. Simple and rapid quantitation of 21 bile acids in rat serum and liver by UPLC-MS-MS: effect of high fat diet on glycine conjugates of rat bile acids. Nagoya J Med Sci. 2013;75:57-71.
16. Sokol RJ, Devereaux M, Khandwala R, O'Brien K. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology. 1993;17:869-881. (Pubitemid 23150097)
17. Perez MJ, Macias RI, Duran C, Monte MJ, Gonzalez-Buitrago JM, Marin JJ. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J Hepatol. 2005;43:324-332. (Pubitemid 40956887)
18. Spiver JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest. 1993;92:17-24. (Pubitemid 23208976)
19. Hardison WG, Grundy SM. Effect of bile acid conjugation pattern on bile acid metabolism in normal humans. Gastroenterology. 1983;84:617-620. (Pubitemid 13191917)
20. Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial translocation in chronic liver disease. Int J Microbiol. 2012;2012:694629.
21. Uchida K, Satoh T, Chikai T, et al. Influencing of cholesterol feeding on bile acid metabolism in young and aged germ-free rats. Jpn J Pharmacol. 1996;71:113-118. (Pubitemid 26235595)
22. Koch MM, Giampieri MP, Lorenzini I, Jezequel AM, Orlandi F. Effect of chenodeoxycholic acid on liver structure and function in man: a stereological and biochemical study. Digestion . 1980;20:8-21. (Pubitemid 10176927)
23. Sokol RJ, Winklhofer-Roob BM, Devereaux MW, McKim JM Jr. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology. 1995;109:1249-1256.
24. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology. 1990;12:486-491. (Pubitemid 20382016)
25. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574-582.
26. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988-997.
27. Jain AK, Stoll B, Burrin DG, Holst JJ, Moore DD. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. Am J Physiol Gastrointest Liver Physiol. 2012;302:G218-G224.
28. He D, Barnes S, Falany CN. Rat liver bile acid CoA:amino acid N-acyltransferase: expression, characterization, and peroxisomal localization. J Lipid Res. 2003;44:2242-2249. (Pubitemid 38082482)
29. Kwakye JB, Johnson MR, Barnes S, Diasio RB. A comparative study of bile acid CoA:amino acid: N-acyltransferase (BAT) from four mammalian species. Comp Biochem Physiol B . 1991;100:131-136.
30. Lake AD, Novak P, Shipkova P, et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol. 2013;268:132-140.
31. Wildgrube HJ, Stockhausen H, Petri J, Fussel U, Lauer H. Naturally occurring conjugated bile acids, measured by high-performance liquid chromatography, in human, dog, and rabbit bile. J Chromatogr. 1986;353:207-213. (Pubitemid 16016344)
32. Ide T, Kano S, Murata M, Yanagita T, Sugano M. Dietary modification of the biliary bile acid glycine:taurine ratio and activity of hepatic bile acid-CoA:amino acid N-acyltransferase (EC 2.3.1) in the rat. Br J Nutr. 1994;72:93-100. (Pubitemid 24220955)
33. Ide T, Horii M. Predominant conjugation with glycine of biliary and lumen bile acids in rats fed on pectin. Br J Nutr. 1989;61:545-557.
34. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of the bile acids. Med Hypotheses. 1986;19:67-69.
35. Hirano F, Haneda M, Makino I. Chenodeoxycholic acid and taurochenodexycholic acid induce anti-apoptotic cIAP-1 expression in human hepatocytes. J Gastroenterol Hepatol. 2006;21:1807-1813. (Pubitemid 44657001)
36. Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD, Gores GJ. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signally cascade. J Biol Chem. 2000;275:20210-20216. (Pubitemid 30441633)
37. Takikawa Y, Miyoshi H, Roberts P, et al. The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes. Gastroenterology. 2001;120:1810-1817. (Pubitemid 32523498)
38. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472-479.
39. Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011-1019.
40. Martinez-Diez MC, Serrano MA, Monte MJ, Marin JJ. Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. Biochim Biophys Acta. 2000;1500:153-160. (Pubitemid 30060387)
41. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol Sci. 2000;57:177-185.
42. Nie B, Park HM, Kazantzis M, et al. Specific bile acids inhibit hepatic fatty acid uptake. Hepatology. 2012;56:1300-1310.